IPO registrations (S-1, F-1) · Registrants
Panbela Therapeutics, Inc.
- SEC CIK
- 1029125 · filings on EDGAR ↗
- Former names
- Sun BioPharma, Inc. (2015–2020); Cimarron Medical, Inc. (2015–2015); CIMARRON SOFTWARE INC (2012–2015)
- Registration
- Form S-1, first filed 2012-05-14, last 2024-08-16; 12 initial registrations, 22 amendments
- Outcome
- Final prospectus filed 2020-08-31; declared effective 2013-02-04; withdrawal requested 2017-12-29
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 712 VISTA BLVD #305, Waconia, MN 55387
- EIN
- 87-0543922
- EDGAR entity type
- operating
- Insiders and CEO pay
- Panbela Therapeutics, Inc. on the corporate pages
On this site
- Business registration: Panbela Therapeutics, Inc. Fuzzy (name and state)
- Business registration: PANBELA THERAPEUTICS, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: PANBELA THERAPEUTICS, INC. EXACT (EIN (EXACT))
- Form D issuer: Panbela Therapeutics, Inc. EXACT (CIK (EXACT))
- SEC filer: CIMARRON SOFTWARE INC EXACT (CIK (EXACT))
Filings 59
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2012-05-14 | S-1 | S-1 (registration) | CIMARRON SOFTWARE INC | 0001477932-12-001525 ↗ |
| 2012-07-12 | S-1/A | S-1/A (amendment) | CIMARRON SOFTWARE INC | 0001477932-12-002245 ↗ |
| 2012-08-10 | S-1/A | S-1/A (amendment) | CIMARRON SOFTWARE INC | 0001477932-12-002848 ↗ |
| 2012-09-13 | S-1/A | S-1/A (amendment) | CIMARRON SOFTWARE INC | 0001477932-12-003630 ↗ |
| 2012-10-09 | S-1/A | S-1/A (amendment) | CIMARRON SOFTWARE INC | 0001477932-12-003825 ↗ |
| 2013-01-15 | S-1/A | S-1/A (amendment) | CIMARRON SOFTWARE INC | 0001477932-13-000220 ↗ |
| 2013-01-31 | S-1/A | S-1/A (amendment) | CIMARRON SOFTWARE INC | 0001477932-13-000451 ↗ |
| 2013-02-04 | EFFECT | EFFECT (declared effective) | CIMARRON SOFTWARE INC | 9999999995-13-000376 ↗ |
| 2014-05-08 | EFFECT | EFFECT (declared effective) | CIMARRON SOFTWARE INC | 9999999995-14-001366 ↗ |
| 2016-09-16 | S-1 | S-1 (registration) | Sun BioPharma, Inc. | 0001437749-16-038827 ↗ |
| 2016-09-30 | EFFECT | EFFECT (declared effective) | Sun BioPharma, Inc. | 9999999995-16-005843 ↗ |
| 2017-09-29 | S-1 | S-1 (registration) | Sun BioPharma, Inc. | 0001437749-17-016546 ↗ |
| 2017-12-04 | S-1/A | S-1/A (amendment) | Sun BioPharma, Inc. | 0001437749-17-020092 ↗ |
| 2017-12-11 | S-1/A | S-1/A (amendment) | Sun BioPharma, Inc. | 0001437749-17-020471 ↗ |
| 2017-12-18 | S-1/A | S-1/A (amendment) | Sun BioPharma, Inc. | 0001437749-17-020818 ↗ |
| 2017-12-29 | RW | RW (withdrawal request) | Sun BioPharma, Inc. | 0001437749-17-021275 ↗ |
| 2020-07-02 | S-1 | S-1 (registration) | Sun BioPharma, Inc. | 0001437749-20-014538 ↗ |
| 2020-08-20 | S-1/A | S-1/A (amendment) | Sun BioPharma, Inc. | 0001437749-20-018408 ↗ |
| 2020-08-26 | S-1/A | S-1/A (amendment) | Sun BioPharma, Inc. | 0001437749-20-018736 ↗ |
| 2020-08-27 | S-1/A | S-1/A (amendment) | Sun BioPharma, Inc. | 0001437749-20-018808 ↗ |
| 2020-08-27 | EFFECT | EFFECT (declared effective) | Sun BioPharma, Inc. | 9999999995-20-002279 ↗ |
| 2020-08-31 | 424B4 | 424B4 (final prospectus) | Sun BioPharma, Inc. | 0001437749-20-018973 ↗ |
| 2021-03-26 | EFFECT | EFFECT (declared effective) | Panbela Therapeutics, Inc. | 9999999995-21-001156 ↗ |
| 2021-05-11 | EFFECT | EFFECT (declared effective) | Panbela Therapeutics, Inc. | 9999999995-21-001891 ↗ |
| 2022-03-28 | EFFECT | EFFECT (declared effective) | Panbela Therapeutics, Inc. | 9999999995-22-000730 ↗ |
| 2022-06-24 | EFFECT | EFFECT (declared effective) | Panbela Therapeutics, Inc. | 9999999995-22-001870 ↗ |
| 2022-06-24 | EFFECT | EFFECT (declared effective) | Panbela Therapeutics, Inc. | 9999999995-22-001871 ↗ |
| 2022-08-19 | S-1 | S-1 (registration) | Panbela Therapeutics, Inc. | 0001437749-22-021058 ↗ |
| 2022-09-06 | S-1/A | S-1/A (amendment) | Panbela Therapeutics, Inc. | 0001437749-22-021839 ↗ |
| 2022-09-29 | EFFECT | EFFECT (declared effective) | Panbela Therapeutics, Inc. | 9999999995-22-002857 ↗ |
| 2022-10-03 | 424B4 | 424B4 (final prospectus) | Panbela Therapeutics, Inc. | 0001437749-22-023497 ↗ |
| 2022-12-16 | S-1 | S-1 (registration) | Panbela Therapeutics, Inc. | 0001437749-22-029280 ↗ |
| 2022-12-27 | S-1/A | S-1/A (amendment) | Panbela Therapeutics, Inc. | 0001437749-22-029781 ↗ |
| 2023-01-18 | S-1/A | S-1/A (amendment) | Panbela Therapeutics, Inc. | 0001437749-23-001188 ↗ |
| 2023-01-20 | S-1/A | S-1/A (amendment) | Panbela Therapeutics, Inc. | 0001437749-23-001375 ↗ |
| 2023-01-23 | S-1/A | S-1/A (amendment) | Panbela Therapeutics, Inc. | 0001437749-23-001522 ↗ |
| 2023-01-25 | EFFECT | EFFECT (declared effective) | Panbela Therapeutics, Inc. | 9999999995-23-000181 ↗ |
| 2023-01-26 | S-1MEF | S-1MEF (added securities) | Panbela Therapeutics, Inc. | 0001437749-23-001839 ↗ |
| 2023-01-30 | 424B4 | 424B4 (final prospectus) | Panbela Therapeutics, Inc. | 0001437749-23-002015 ↗ |
| 2023-02-10 | S-1 | S-1 (registration) | Panbela Therapeutics, Inc. | 0001437749-23-003062 ↗ |
| 2023-02-14 | EFFECT | EFFECT (declared effective) | Panbela Therapeutics, Inc. | 9999999995-23-000436 ↗ |
| 2023-03-23 | EFFECT | EFFECT (declared effective) | Panbela Therapeutics, Inc. | 9999999995-23-000642 ↗ |
| 2023-05-08 | S-1 | S-1 (registration) | Panbela Therapeutics, Inc. | 0001437749-23-013019 ↗ |
| 2023-06-02 | S-1/A | S-1/A (amendment) | Panbela Therapeutics, Inc. | 0001437749-23-016513 ↗ |
| 2023-06-15 | EFFECT | EFFECT (declared effective) | Panbela Therapeutics, Inc. | 9999999995-23-001767 ↗ |
| 2023-06-20 | 424B4 | 424B4 (final prospectus) | Panbela Therapeutics, Inc. | 0001437749-23-017878 ↗ |
| 2023-11-22 | S-1 | S-1 (registration) | Panbela Therapeutics, Inc. | 0001437749-23-032913 ↗ |
| 2023-12-20 | EFFECT | EFFECT (declared effective) | Panbela Therapeutics, Inc. | 9999999995-23-003696 ↗ |
| 2024-01-04 | S-1 | S-1 (registration) | Panbela Therapeutics, Inc. | 0001437749-24-000444 ↗ |
| 2024-01-22 | S-1/A | S-1/A (amendment) | Panbela Therapeutics, Inc. | 0001437749-24-001785 ↗ |
| 2024-01-25 | S-1/A | S-1/A (amendment) | Panbela Therapeutics, Inc. | 0001437749-24-002121 ↗ |
| 2024-01-25 | S-1/A | S-1/A (amendment) | Panbela Therapeutics, Inc. | 0001437749-24-002145 ↗ |
| 2024-01-26 | EFFECT | EFFECT (declared effective) | Panbela Therapeutics, Inc. | 9999999995-24-000228 ↗ |
| 2024-01-30 | 424B4 | 424B4 (final prospectus) | Panbela Therapeutics, Inc. | 0001437749-24-002585 ↗ |
| 2024-03-29 | S-1 | S-1 (registration) | Panbela Therapeutics, Inc. | 0001437749-24-010122 ↗ |
| 2024-04-02 | EFFECT | EFFECT (declared effective) | Panbela Therapeutics, Inc. | 9999999995-24-000831 ↗ |
| 2024-04-15 | EFFECT | EFFECT (declared effective) | Panbela Therapeutics, Inc. | 9999999995-24-000986 ↗ |
| 2024-04-18 | S-1 | S-1 (registration) | Panbela Therapeutics, Inc. | 0001437749-24-012445 ↗ |
| 2024-08-16 | S-1/A | S-1/A (amendment) | Panbela Therapeutics, Inc. | 0001437749-24-027110 ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Fuhrman David Michael | Director,Officer,TenPercentOwner; Other | President and CEO | 3 | 2015 | |
| Sargent Robert John | Director,TenPercentOwner; Other | 3 | 2015 | ||
| Cullen Michael T. | Director; Director,Officer; Director,Officer,TenPercentOwner; Director,TenPercentOwner | Exec. Chairman, Pres. & CEO; Executive Chairman | 20 | 2015–2023 | |
| Gagnon Suzanne | Director; Director,Officer | Chief Medical Officer | 12 | 2015–2021 | |
| GILBERTSON RYAN RANDALL | TenPercentOwner | 7 | 2015–2019 | ||
| KAYSEN DAVID B | Director,Officer; Officer | President and CEO | 6 | 2015–2018 | |
| Neenan Thomas X. | Director,Officer | Chief Scientific Officer | 1 | 2015 | |
| Ryweck Daniel E. | Officer | Chief Financial Officer | 1 | 2015 | |
| Schaffer Paul W. | Director | 13 | 2015–2021 | ||
| Schemel Donald Robert | Director; Director,TenPercentOwner | 10 | 2015–2023 | ||
| MATHIESEN JEFFREY S | Director | 8 | 2015–2023 | ||
| PAULSON J ROBERT JR | Director | 2 | 2015–2016 | ||
| Kellen Scott | Officer | Chief Financial Officer | 6 | 2015–2018 | |
| Gill Dalvir S | Director | 2 | 2016 | ||
| Horvath Susan | Officer | V.P. of Finance & CFO | 15 | 2018–2024 | |
| Ryan R. Gilbertson 2012 Irrevocable Trust | TenPercentOwner | 1 | 2019 | ||
| Fratamico Arthur | Director | 7 | 2019–2023 | ||
| Simpson Jennifer K. | Director,Officer | President and CEO | 9 | 2020–2024 | |
| Donovan Daniel | Director | 2 | 2022–2023 | ||
| Jacob Jeffrey E. | Director | 4 | 2022–2023 | ||
| GOLDMAN SACHS & CO. LLC | TenPercentOwner | 2 | 2023 | ||
| GOLDMAN SACHS GROUP INC | TenPercentOwner | 2 | 2023 | ||
| Nant Capital, LLC | TenPercentOwner | 2 | 2024 | ||
| SOON-SHIONG PATRICK | TenPercentOwner | 2 | 2024 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2024-01-05 | Panbela Therapeutics, Inc. | Pharmaceuticals | Indefinite | $2,000,000 | 2 | 1 |
| 2023-11-17 | Panbela Therapeutics, Inc. | Pharmaceuticals | Indefinite | $3,322,800 | 3 | 1 |
| 2022-06-29 | Panbela Therapeutics, Inc. | Pharmaceuticals | Indefinite | $8,800,000 | 70 | 1 |
| 2019-09-09 | Sun BioPharma, Inc. | Pharmaceuticals | Indefinite | $2,500,000 | 38 | 1 |
| 2019-01-04 | Sun BioPharma, Inc. | Pharmaceuticals | $2,000,000 | $1,358,638 | 15 | 1 |
| 2018-03-06 | Sun BioPharma, Inc. | Pharmaceuticals | $20,000,000 | $840,000 | 13 | 1 |
| 2017-03-06 | Sun BioPharma, Inc. | Pharmaceuticals | $5,000,000 | $1,495,000 | 14 | 1 |
| 2016-06-27 | Sun BioPharma, Inc. | Pharmaceuticals | $5,000,000 | $1,951,000 | 27 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.